Therapy Areas: Autoimmune
Minghui Pharmaceutical presents MHB018A Phase I/II results for thyroid eye disease at ENDO 2026
16 June 2026 - Minghui Pharmaceutical, a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, announced on Monday the presenta...
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
10 June 2026 - US healthcare company Organon (NYSE:OGN) on Wednesday announced US Food and Drug Administration (FDA) approval of a supplemental Biologics License Application for TOFIDENCE (tocilizumab...
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
10 June 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, announced on Tuesday that its partner, Formation Bio, ...
Antengene granted IND approval in China for ATG-201 in autoimmune disease
10 June 2026 - Chinese biotech company Antengene Corporation Limited (SEHK:6996) announced on Tuesday that China's National Medical Products Administration (NMPA) has approved the Investigational...
Antengene presents first ATG-207 preclinical data at EULAR 2026
8 June 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996) announced on Sunday that it has presented the first preclinical data on ATG-207, alpha masked and TGF beta RIII...
Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline
5 June 2026 - Biopharmaceutical company Gilead Sciences Inc (Nasdaq: GILD) and biotechnology company Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT), formerly known as Galapagos, confirmed ...